The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Abstract
BACKGROUND: Interferon beta is an effective treatment for relapsing multiple sclerosis (MS). As with other protein drugs, neutralizing antibodies (NAB) can develop that reduce the effectiveness of treatment. OBJECTIVES: To determine the incidence and biological significance of NAB to interferon beta-la (IFN-beta-1a; Avonex; Biogen, Cambridge, MA) in MS patients. METHODS: A two-step assay for NAB to IFN-beta-1a was developed and used to assay serum samples from participants in the phase III clinical trial of IFN-beta-1a, and from patients in an ongoing open-label study of IFN-beta-1a. The biological significance of NAB to IFN-beta-1a was determined by relating the NAB assay result to in vivo induction of the IFN-inducible molecules neopterin and beta-2 microglobulin, and the clinical significance was determined by comparing clinical and MRI measures of disease activity after 2 years of IFN-beta-1a therapy in patients who were NAB+ and NAB-. The incidence of NAB was compared in MS patients who had used only IFN-beta-1a with the incidence in MS patients who had used only IFN-beta-1b. RESULTS: In patients in the open-label study, development of NAB to IFN-beta-1a resulted in a titer-dependent reduction in neopterin induction after interferon injections. In patients in the phase III study, development of NAB was associated with a reduction in beta-2 microglobulin induction. In the phase III study, a trend toward reduced benefit of IFN-beta-1a on MRI activity in NAB+ versus NAB- patients was observed. The incidence of NAB to IFN-beta-1a in the open-label study was approximately 5% over 24 months of treatment of IFN-beta-1a therapy, but was four- to sixfold higher using the same assay for patients exposed only to IFN-beta-1b for a similar duration. There were no clinical, MRI, or CSF characteristics that were predictive of which patients would develop NAB. CONCLUSIONS: NAB directed against IFN-beta have in vivo biological consequences in patients with MS. The frequency with which MS patients develop NAB against IFN-beta is significantly greater with IFN-beta-1b therapy compared with IFN-beta-1a therapy. Treatment decisions in MS patients treated with IFN-beta should take into account development of NAB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Self-citationQin, J., Clore, G. M., & Gronenborn, A. M. (1996) · Biochemistry · doi:10.1021/bi952299h · Cited by 88
Specific Binding of the ETS-Domain Protein to the Interferon-Stimulated Response Element
Rutherford, M., KUMAR, A., Haque, S. J., Ghysdael, J., & Williams, B. R. G. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.1 · Cited by 15
Cited by
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Self-citationBastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Manry, J., Michailidis, E., Hoffmann, H.-H., Eto, S., Garcia-Prat, M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4340 · Cited by 610
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G. R., Fischer, J. S., Goodman, A. D., Heidenreich, F. R., Kooijmans, M. F., Sandrock, A. W., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 402
Self-citationSorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14541-2 · Cited by 383
Metadata
- Authors
- Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., Mass, M. K., Richert, J. R., Salazar, A. M., Munschauer, F. E., Cookfair, D. L., Simon, J. H., Jacobs, L. D., & The Multiple Sclerosis Collaborative Research Group (MSCRG)*
- Venue
- Neurology
- Published
- 1998-05
- Volume
- 50
- Issue
- 5
- Pages
- 1266-1272
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2164542304
- Cited by
- 333
- References
- 3
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.50.5.1266
- The paper
- Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., Mass, M. K., Richert, J. R., Salazar, A. M., Munschauer, F. E., Cookfair, D. L., Simon, J. H., Jacobs, L. D., & The Multiple Sclerosis Collaborative Research Group (MSCRG)*. (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.50.5.1266
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.